Cipla's portable, wireless spirometer to ease diagnosis of COPD, asthma
Mumbai/IBNS: Indian multinational pharma giant Cipla Limited (BSE: 500087; NSE: CIPLA EQ) Wednesday announced the launch of Spirofy, India's first pneumotach based portable, wireless spirometer, on World COPD Day, the company said in a BSE filing.
"With this launch, the company intends to revolutionise Obstructive Airway Disease (OAD) diagnosis, in line with its ambition to strengthen its position as the lung leader in India. This a part of the Company’s #LungAttack campaign that endeavors to drive awareness about COPD and encourage early diagnosis," the statement read.
Currently, COPD remains the second most common cause of death in India after heart diseases, where India alone bears 32 percent of the global COPD burden.
The device has been developed after five years of meticulous in-house research by the Integrated Product Development (IPD) team, and is aimed at transforming Obstructive Airway Disease (OAD) diagnosis in India.
Cipla said Spirofy is wireless and is bult to provide good battery back up making it suitable for use in outdoor camps, remote areas with power shortages, or simply providing physicians' flexibility and ease of use.
"This advanced device ensures high result accuracy and individual patient safety using Bacterial Viral Filters," it said.
The device generates reports in real-time, which can be printed using a portable wireless thermal printer instantly, or a pdf version can be shared on the phone.
The Indian drug major said it will train physicians in the interpretation of spirometry results.
Conventional spirometers are bulky, have complex functionality and need regular maintenance. These factors hindered its widespread acceptance by medical professionals though spirometry is the gold standard for COPD diagnosis.
This resulted in underdiagnosis or misdiagnosis of COPD cases in India.
Commenting on the launch, Umang Vohra (MD and Global CEO, Cipla Limited) said, "Cipla has been steadfastly focused on addressing the world's growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD. The Spirofy launch aims to help doctors across the country to improve lives of patients through accurate and affordable diagnosis."
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.